AbbVie has revealed the Phase II study results of the investigational medicine veliparib in patients with non-small cell lung cancer (NSCLC).
The veliparib combined with the chemotherapy regimen carboplatin and paclitaxel demonstrated an improvement in median progression-free survival (PFS) in patients with previously untreated metastatic or advanced NSCLC who are current smokers.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Veliparib is an investigational oral poly is an investigational oral poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor, which is being assessed to treat various cancer types, including NSCLC.
AbbVie oncology clinical development vice president Dr Gary Gordon said: "The results from this study reinforce AbbVie’s continued investigation of veliparib in treating advanced non-small cell lung cancer, including patients with a history of smoking."
The Phase II trial assessed survival outcomes in previously untreated metastatic or advanced NSCLC patients treated with either a regimen consisting of a carboplatin, paclitaxel (C/P) or carboplatin, paclitaxel combined with veliparib (V+C/P).
The study also evaluated patients based on their smoking status and each experimental arm of the 158 patient study comprised current smokers, former smokers and non-smoker subgroups.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAccording to the firm, current smokers treated with V+C/P had a median PFS of 5.6 months compared against 3.3 months for patients treated with C/P alone and non-smokers treated with V+C/P had a median PFS of 6.4 months compared to 5.6 months in patients treated with C/P alone.
In addition, current smokers treated with V+C/P had a median overall survival of 12.5 months compared to 5.4 months for patients treated with C/P alone and former smokers treated with V+C/P had a median overall survival of 8.6 months compared to 14.67 months with those treated with C/P alone, the company said.
